Erlosiban, also known as OBE001, is a novel, orally active nonpeptide oxytocin receptor antagonist under development for the treatment of preterm labor and improvement in embryo implantation and pregnancy rate in assisted reproductive technology (ART).
Divarasib (GDC-6036) adipate is a selective and highly potent KRAS G12C inhibitor with an impressively low IC 50 value of <0.01 μM, designed for oral administration. It covalently attaches to the switch II (SW-II) pocket in KRAS G12C, irreversibly maintaining the protein in its inactive GDP-bound state [1] [2].